Demographic characteristics and number of months of taking hormonal contraceptive pills in women with fibroadenoma

Due to the relatively high prevalence of benign breast diseases in women and the hormonal relationship in puberty and regulating the growth rate of epithelial cells and stromal cells of the breast, more attention to these effective hormonal factors will be effective in reducing the prevalence of these diseases.

In this descriptive-analytical study, 610 women referred to Khatam Al-Anbia Breast Cancer Clinic in Jahrom participated in 2019. The data collection tool in this study was a researcher-made questionnaire that the validity of this questionnaire was determined by 5 professors of the Department of Surgery and Obstetrics and its reliability was determined by Cronbachchr('39')s alpha test of 85%.

610 women aged 20-60 years who referred to Khatamah Al-Anbia Clinic in Jahrom participated in the study. The history of hyperlipidemia in women participating in the study had the highest frequency in fibroadenoma and non-fibroadenoma groups. Also in the fibroadenoma group, 30.2% of women were overweight and 10.4% obese, while in the group without fibroadenoma, 43.7% of women were overweight and 24.6% were obese. Regarding the use of hormonal drugs, the results of logistic regression by modulating the effect of age and BMI showed that the duration of use of OCP, OR = 0.93 (CI: 0.55,1.56)) was not significantly associated with the chance of developing benign breast masses (PV: 0.78)

The results of this study showed that the use of birth control pills (OCP) is not associated with the occurrence of benign breast diseases.